Erdheim-Chester Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Erdheim-Chester disease markets are expected to exhibit a CAGR of 7.13% during 2024-2034.
The Erdheim-Chester disease market has been comprehensively analyzed in IMARC's new report titled "Erdheim-Chester Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Erdheim-Chester disease (ECD) is an exceedingly rare form of non-Langerhans cell histiocytosis, characterized by the abnormal accumulation of immune cells in various organs and tissues. This disorder primarily affects adults, with an average onset age of around 53 years. ECD's symptoms can vary widely, depending on the organs involved. Common manifestations include bone pain, weight loss, fatigue, and cardiovascular complications due to the infiltration of histiocytes. Numerous other symptoms might include neurological deficits, skin abnormalities, and endocrine dysfunction. The diagnosis of ECD poses challenges due to its similarity to other disorders and the limited understanding of its underlying mechanisms. The healthcare provider often performs a combination of clinical evaluation, imaging techniques like MRI, and histopathological analysis of biopsied tissues to confirm the presence of infiltrating histiocytes in patients. Genetic studies and molecular analyses might also be recommended to obtain insights about the disease's genetic basis and potential treatment targets.
The increasing prevalence of somatic mutations affecting the BRAF gene, which can trigger the excessive growth of specific cells within various tissues, is primarily driving the Erdheim-Chester disease market. In addition to this, the inflating utilization of advanced therapeutic agents, such as targeted kinase inhibitors, immune checkpoint inhibitors, and interferon-alpha to manage the ailment effectively and curb further progression is creating a positive outlook for the market. Moreover, the widespread adoption of supportive treatments, encompassing pain management strategies and bisphosphonate therapy, which aid in alleviating symptoms and reinforcing bone integrity, is also bolstering the market growth. Apart from this, the rising usage of cutting-edge imaging techniques, such as positron emission tomography-computed tomography (PET-CT) scans, to enable precise disease monitoring and accurate assessment of treatment outcomes in individuals suffering from the illness is acting as another significant growth-inducing factor. Additionally, the emerging popularity of regenerative medicine, like stem cell transplantation procedures, which aim to mitigate tissue damage and reverse ailment manifestations in patients, is also augmenting the market growth. Furthermore, the escalating application of gene editing techniques, such as CRISPR, that are aimed at directly repairing or deactivating the mutated BRAF gene, is expected to drive the Erdheim-Chester disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Erdheim-Chester disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Erdheim-Chester disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Erdheim-Chester disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Erdheim-Chester disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Erdheim-Chester disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current Erdheim-Chester disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the Erdheim-Chester disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Erdheim-Chester disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Erdheim-Chester disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Erdheim-Chester disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Erdheim-Chester disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Erdheim-Chester disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Erdheim-Chester disease across the seven major markets?
What is the size of the Erdheim-Chester disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Erdheim-Chester disease?
What will be the growth rate of patients across the seven major markets?
Erdheim-Chester Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Erdheim-Chester disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Erdheim-Chester disease market?
What are the key regulatory events related to the Erdheim-Chester disease market?
What is the structure of clinical trial landscape by status related to the Erdheim-Chester disease market?
What is the structure of clinical trial landscape by phase related to the Erdheim-Chester disease market?
What is the structure of clinical trial landscape by route of administration related to the Erdheim-Chester disease market?
The Erdheim-Chester disease market has been comprehensively analyzed in IMARC's new report titled "Erdheim-Chester Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Erdheim-Chester disease (ECD) is an exceedingly rare form of non-Langerhans cell histiocytosis, characterized by the abnormal accumulation of immune cells in various organs and tissues. This disorder primarily affects adults, with an average onset age of around 53 years. ECD's symptoms can vary widely, depending on the organs involved. Common manifestations include bone pain, weight loss, fatigue, and cardiovascular complications due to the infiltration of histiocytes. Numerous other symptoms might include neurological deficits, skin abnormalities, and endocrine dysfunction. The diagnosis of ECD poses challenges due to its similarity to other disorders and the limited understanding of its underlying mechanisms. The healthcare provider often performs a combination of clinical evaluation, imaging techniques like MRI, and histopathological analysis of biopsied tissues to confirm the presence of infiltrating histiocytes in patients. Genetic studies and molecular analyses might also be recommended to obtain insights about the disease's genetic basis and potential treatment targets.
The increasing prevalence of somatic mutations affecting the BRAF gene, which can trigger the excessive growth of specific cells within various tissues, is primarily driving the Erdheim-Chester disease market. In addition to this, the inflating utilization of advanced therapeutic agents, such as targeted kinase inhibitors, immune checkpoint inhibitors, and interferon-alpha to manage the ailment effectively and curb further progression is creating a positive outlook for the market. Moreover, the widespread adoption of supportive treatments, encompassing pain management strategies and bisphosphonate therapy, which aid in alleviating symptoms and reinforcing bone integrity, is also bolstering the market growth. Apart from this, the rising usage of cutting-edge imaging techniques, such as positron emission tomography-computed tomography (PET-CT) scans, to enable precise disease monitoring and accurate assessment of treatment outcomes in individuals suffering from the illness is acting as another significant growth-inducing factor. Additionally, the emerging popularity of regenerative medicine, like stem cell transplantation procedures, which aim to mitigate tissue damage and reverse ailment manifestations in patients, is also augmenting the market growth. Furthermore, the escalating application of gene editing techniques, such as CRISPR, that are aimed at directly repairing or deactivating the mutated BRAF gene, is expected to drive the Erdheim-Chester disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Erdheim-Chester disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Erdheim-Chester disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Erdheim-Chester disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Erdheim-Chester disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Erdheim-Chester disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current Erdheim-Chester disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the Erdheim-Chester disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Erdheim-Chester disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Erdheim-Chester disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Erdheim-Chester disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Erdheim-Chester disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Erdheim-Chester disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Erdheim-Chester disease across the seven major markets?
What is the size of the Erdheim-Chester disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Erdheim-Chester disease?
What will be the growth rate of patients across the seven major markets?
Erdheim-Chester Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Erdheim-Chester disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Erdheim-Chester disease market?
What are the key regulatory events related to the Erdheim-Chester disease market?
What is the structure of clinical trial landscape by status related to the Erdheim-Chester disease market?
What is the structure of clinical trial landscape by phase related to the Erdheim-Chester disease market?
What is the structure of clinical trial landscape by route of administration related to the Erdheim-Chester disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ERDHEIM-CHESTER DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ERDHEIM-CHESTER DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ERDHEIM-CHESTER DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (??2018-2034?)
7.2.4 Epidemiology by Gender (??2018-2034?)
7.2.5 Diagnosed Cases (??2018-2034?)
7.2.6 Patient Pool/Treated Cases (??2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (??2018-2034?)
7.3.4 Epidemiology by Gender (??2018-2034?)
7.3.5 Diagnosed Cases (??2018-2034?)
7.3.6 Patient Pool/Treated Cases (??2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (??2018-2034?)
7.4.4 Epidemiology by Gender (??2018-2034?)
7.4.5 Diagnosed Cases (??2018-2034?)
7.4.6 Patient Pool/Treated Cases (??2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (??2018-2034?)
7.5.4 Epidemiology by Gender (??2018-2034?)
7.5.5 Diagnosed Cases (??2018-2034?)
7.5.6 Patient Pool/Treated Cases (??2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (??2018-2034?)
7.6.4 Epidemiology by Gender (??2018-2034?)
7.6.5 Diagnosed Cases (??2018-2034?)
7.6.6 Patient Pool/Treated Cases (??2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (??2018-2034?)
7.7.4 Epidemiology by Gender (??2018-2034?)
7.7.5 Diagnosed Cases (??2018-2034?)
7.7.6 Patient Pool/Treated Cases (??2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (??2018-2034?)
7.8.4 Epidemiology by Gender (??2018-2034?)
7.8.5 Diagnosed Cases (??2018-2034?)
7.8.6 Patient Pool/Treated Cases (??2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (??2018-2034?)
7.9.4 Epidemiology by Gender (??2018-2034?)
7.9.5 Diagnosed Cases (??2018-2034?)
7.9.6 Patient Pool/Treated Cases (??2018-2034?)
8 ERDHEIM-CHESTER DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ERDHEIM-CHESTER DISEASE - UNMET NEEDS
10 ERDHEIM-CHESTER DISEASE - KEY ENDPOINTS OF TREATMENT
11 ERDHEIM-CHESTER DISEASE - MARKETED PRODUCTS
11.1 List of Erdheim-Chester Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Cotellic (Cobimetinib) - Genentech/Exelixis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ERDHEIM-CHESTER DISEASE - PIPELINE DRUGS
12.1 List of Erdheim-Chester Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ERDHEIM-CHESTER DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ERDHEIM-CHESTER DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ERDHEIM-CHESTER DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Erdheim-Chester Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Erdheim-Chester Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Erdheim-Chester Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Erdheim-Chester Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Erdheim-Chester Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Erdheim-Chester Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Erdheim-Chester Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Erdheim-Chester Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Erdheim-Chester Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Erdheim-Chester Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Erdheim-Chester Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Erdheim-Chester Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Erdheim-Chester Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Erdheim-Chester Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Erdheim-Chester Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Erdheim-Chester Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Erdheim-Chester Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Erdheim-Chester Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Erdheim-Chester Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Erdheim-Chester Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Erdheim-Chester Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Erdheim-Chester Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Erdheim-Chester Disease - Access and Reimbursement Overview
16 ERDHEIM-CHESTER DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ERDHEIM-CHESTER DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ERDHEIM-CHESTER DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ERDHEIM-CHESTER DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ERDHEIM-CHESTER DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ERDHEIM-CHESTER DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (??2018-2034?)
7.2.4 Epidemiology by Gender (??2018-2034?)
7.2.5 Diagnosed Cases (??2018-2034?)
7.2.6 Patient Pool/Treated Cases (??2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (??2018-2034?)
7.3.4 Epidemiology by Gender (??2018-2034?)
7.3.5 Diagnosed Cases (??2018-2034?)
7.3.6 Patient Pool/Treated Cases (??2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (??2018-2034?)
7.4.4 Epidemiology by Gender (??2018-2034?)
7.4.5 Diagnosed Cases (??2018-2034?)
7.4.6 Patient Pool/Treated Cases (??2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (??2018-2034?)
7.5.4 Epidemiology by Gender (??2018-2034?)
7.5.5 Diagnosed Cases (??2018-2034?)
7.5.6 Patient Pool/Treated Cases (??2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (??2018-2034?)
7.6.4 Epidemiology by Gender (??2018-2034?)
7.6.5 Diagnosed Cases (??2018-2034?)
7.6.6 Patient Pool/Treated Cases (??2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (??2018-2034?)
7.7.4 Epidemiology by Gender (??2018-2034?)
7.7.5 Diagnosed Cases (??2018-2034?)
7.7.6 Patient Pool/Treated Cases (??2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (??2018-2034?)
7.8.4 Epidemiology by Gender (??2018-2034?)
7.8.5 Diagnosed Cases (??2018-2034?)
7.8.6 Patient Pool/Treated Cases (??2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (??2018-2034?)
7.9.4 Epidemiology by Gender (??2018-2034?)
7.9.5 Diagnosed Cases (??2018-2034?)
7.9.6 Patient Pool/Treated Cases (??2018-2034?)
8 ERDHEIM-CHESTER DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ERDHEIM-CHESTER DISEASE - UNMET NEEDS
10 ERDHEIM-CHESTER DISEASE - KEY ENDPOINTS OF TREATMENT
11 ERDHEIM-CHESTER DISEASE - MARKETED PRODUCTS
11.1 List of Erdheim-Chester Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Cotellic (Cobimetinib) - Genentech/Exelixis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ERDHEIM-CHESTER DISEASE - PIPELINE DRUGS
12.1 List of Erdheim-Chester Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ERDHEIM-CHESTER DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ERDHEIM-CHESTER DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ERDHEIM-CHESTER DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Erdheim-Chester Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Erdheim-Chester Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Erdheim-Chester Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Erdheim-Chester Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Erdheim-Chester Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Erdheim-Chester Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Erdheim-Chester Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Erdheim-Chester Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Erdheim-Chester Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Erdheim-Chester Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Erdheim-Chester Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Erdheim-Chester Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Erdheim-Chester Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Erdheim-Chester Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Erdheim-Chester Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Erdheim-Chester Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Erdheim-Chester Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Erdheim-Chester Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Erdheim-Chester Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Erdheim-Chester Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Erdheim-Chester Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Erdheim-Chester Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Erdheim-Chester Disease - Access and Reimbursement Overview
16 ERDHEIM-CHESTER DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ERDHEIM-CHESTER DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ERDHEIM-CHESTER DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
